A5018961222- Rheumatoid Arthritis Research and Therapies
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Toxin Mechanisms and Immunotoxins
- Peripheral Neuropathies and Disorders
- Pharmacological Effects of Natural Compounds
- Inflammatory mediators and NSAID effects
- Medicinal plant effects and applications
- Cytokine Signaling Pathways and Interactions
- Medical and Biological Sciences
- Healthcare Systems and Public Health
- Systemic Lupus Erythematosus Research
- Biosimilars and Bioanalytical Methods
- Systemic Sclerosis and Related Diseases
- Osteoarthritis Treatment and Mechanisms
- Tuberculosis Research and Epidemiology
- Inflammatory Myopathies and Dermatomyositis
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Immunodeficiency and Autoimmune Disorders
- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
Samara Regional Clinical Oncology Center
2014-2021
Samara Regional Clinical Hospital named after V.D. Seredavina
2016-2021
Система комплексной поддержки и сопровождения научного журнала Elpub позволяет запустить двуязычный сайт со встроенной системой электронной редакции в соответствии с лучшими издательскими практиками, а так же предусматривает техническую методическую поддержку стороны специалистов НЭИКОН.
The JAK inhibitor tofacitinib (TOFA) blocks the intracellular signaling pathway that activates synthesis of cytokines and mediators involved in development pain central sensitization (CS), which determines rapid analgesic effect. However, it is not clear how reduction associated with achieving low activity rheumatoid arthritis (RA). aim study was to assess relationship between early clinical response a decrease after 3 6 months. Material methods. group consisted 88 RA patients (age – 53±11.5...
To determine the possible boundaries of high-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HDIT-autoHSCT) for autoimmune diseases (AUDs), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS).A long-term trial was conducted at one center to evaluate efficiency safety HDIT-autoHSCT in patients with AUDs. The previous standard noted be resistant or lowly effective. age 10 connective tissue 27.6±2.8 years;...
Tofacitinib (TOFA), a member of new class targeted synthetic disease-modifying antirheumatic drugs (DMARDs), is promising medication for the treatment rheumatoid arthritis (RA) and other immunoinflammatory diseases. The paper describes Russian experi-ence with TOFA used to treat severe RA. Patients methods. 101 RA patients (18 men 83 women; mean age, 51.03±11.28 years; disease duration, 105.4±81.43 months) who were positive for factor (89.1%) anti-cyclic citrullinated peptide antibodies...
Tofacitinib (TOFA), a representative of new class targeted synthetic disease-modifying antirheumatic drugs (s-DMARD), is promising drug for treating rheumatoid arthritis (RA) and other immune inflammatory diseases. Objective: to evaluate the efficiency safety therapy with TOFA in combination methotrexate (MTX) s-DMARDs real clinical practice patients active RA previous ineffective therapy. Patients methods. A 6-month Russian multicenter study function quality life enrolled 101 resistant RA:...
A combination of chondroitin and glucosamine is widely used in clinical practice as both a symptomatic structure-modifying agent for the treatment osteoarthritis (OA). The emergence new drugs based on this substantially expands options OA therapy. Objective : to evaluate efficacy safety Artroflex® that sulfate 400 mg 500 (CS + GS) support joint health patients with knee and/or hip OA. Patients methods . When implementing an open observational research program, results using CS GS complex...
Janus kinase (JK) inhibitors block the intracellular signaling pathways that are responsible for synthesis of proinflammatory cytokines and mediators, which in turn cause activation pain receptors central sensitization (CS). It is suggested JK can rapidly eliminate reduce severity CS. Objective : to evaluate effect inhibitor tofacitinib (TOFA) on intensity signs CS patients with active rheumatoid arthritis (RA) at 7 28 days after therapy initiation. Patients methods . A study group consisted...
Background: The presence of central sensitization (CS) significantly burdens the course rheumatoid arthritis (RA). JAK inhibitors block intracellular signal pathways including ones responsible for synthesis mediators and cytokines causing pain CS. application is supposed to relieve reduce CS severity promptly. Objectives: To evaluate inhibitor effect on signs in patients with active RA 7 28 days after start therapy. Methods: Study group included 39 RA, their age was 50.9±11.1, 79.5% women,...
Background: JAK inhibitors block intracellular signaling pathways responsible for the synthesis of cytokines and mediators involved in development chronic pain central sensitization (CS). This determines a very rapid clinical response to inhibitors. However, it is not clear how significant reduction first weeks therapy associated with achievement low rheumatoid arthritis (RA) activity. Objectives: assess relationship between early tofacitinib decrease RA activity after 3 6 months. Methods:...
Methotrexate or leflunomide is used as a first-line synthetic disease-modifying anti-rheumatic drug in the therapy of rheumatoid arthritis (RA). In 2011, Russian Federation registered and since it has been successfully using leflunomide**. Objective: to evaluate efficacy tolerability leflunomide** treat RA routine clinical practice. Subjects methods. The investigation enrolled patients with varying duration that met 1987 classification criteria. were followed up 33 healthcare facilities...
<h3>Background</h3> Tofacitinib (TOFA) was approved in Russia for treatment of patients with rheumatoid arthritis (RA) 2013, but published information about its post-approval use limited to some individual clinical observations. <h3>Objectives</h3> To study the efficacy and safety TOFA severe active RA practice. <h3>Methods</h3> We present preliminary results ongoing investigator initiated "Local open label multicenter observational insufficient response DMARDs", a part research program...
<h3>Background</h3> Tofacitinib (TOFA) is so far the only representative of a new class Jak-kinase inhibitors in rheumatology. Despite extensive data on TOFA obtained from 3rd phase studies, for use clinical practice, information limited. <h3>Objectives</h3> To study efficacy and safety RA practice. <h3>Methods</h3> We represent combined two parallel IV Phase open-label observational trials, modelling conducted by very similar protocols 11 rheumatology centers Russia. Inclusion criteria were...
Background: Currently it is unclear whether combination of tofacitinib (tofa) with methotrexate (Mtx) more effective and safe than tofa in monotherapy. Objectives: To compare efficacy safety monotherapy mtx RA patients. Methods: Data from 450 patients Russian national register OREL were included the statistical analysis. 1st, 6, 12, 24 36 month after baseline analyzed. Demographical disease-related characteristics (symptoms duration, DAS28, CDAI, SDAI, number tender swollen joints (NTJ,...